Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more
Identifieur interne : 000B35 ( Istex/Corpus ); précédent : 000B34; suivant : 000B36Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more
Auteurs : Codrin Lungu ; Barbara I. Karp ; Katharine Alter ; Regina Zolbrod ; Mark HallettSource :
- Movement Disorders [ 0885-3185 ] ; 2011-03.
English descriptors
- KwdEn :
Abstract
Background:: Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more. Methods:: Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using t tests and Pearson correlations. Results:: Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side‐effects, but benefit magnitude predicted longer compliance. No serious side‐effects or antibody‐mediated resistance occurred. Conclusion:: This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23504
Links to Exploration step
ISTEX:B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title><author><name sortKey="Lungu, Codrin" sort="Lungu, Codrin" uniqKey="Lungu C" first="Codrin" last="Lungu">Codrin Lungu</name><affiliation><mods:affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Karp, Barbara I" sort="Karp, Barbara I" uniqKey="Karp B" first="Barbara I." last="Karp">Barbara I. Karp</name><affiliation><mods:affiliation>Combined Neuroscience IRB, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Alter, Katharine" sort="Alter, Katharine" uniqKey="Alter K" first="Katharine" last="Alter">Katharine Alter</name><affiliation><mods:affiliation>Physical Disabilities Section, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Zolbrod, Regina" sort="Zolbrod, Regina" uniqKey="Zolbrod R" first="Regina" last="Zolbrod">Regina Zolbrod</name><affiliation><mods:affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Hallett, Mark" sort="Hallett, Mark" uniqKey="Hallett M" first="Mark" last="Hallett">Mark Hallett</name><affiliation><mods:affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23504</idno><idno type="url">https://api.istex.fr/document/B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title><author><name sortKey="Lungu, Codrin" sort="Lungu, Codrin" uniqKey="Lungu C" first="Codrin" last="Lungu">Codrin Lungu</name><affiliation><mods:affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Karp, Barbara I" sort="Karp, Barbara I" uniqKey="Karp B" first="Barbara I." last="Karp">Barbara I. Karp</name><affiliation><mods:affiliation>Combined Neuroscience IRB, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Alter, Katharine" sort="Alter, Katharine" uniqKey="Alter K" first="Katharine" last="Alter">Katharine Alter</name><affiliation><mods:affiliation>Physical Disabilities Section, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Zolbrod, Regina" sort="Zolbrod, Regina" uniqKey="Zolbrod R" first="Regina" last="Zolbrod">Regina Zolbrod</name><affiliation><mods:affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Hallett, Mark" sort="Hallett, Mark" uniqKey="Hallett M" first="Mark" last="Hallett">Mark Hallett</name><affiliation><mods:affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-03">2011-03</date><biblScope unit="vol">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="750">750</biblScope><biblScope unit="page" to="753">753</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D</idno><idno type="DOI">10.1002/mds.23504</idno><idno type="ArticleID">MDS23504</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>botulinum</term><term>dystonia</term><term>efficacy</term><term>focal hand dystonia</term><term>safety</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background:: Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more. Methods:: Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using t tests and Pearson correlations. Results:: Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side‐effects, but benefit magnitude predicted longer compliance. No serious side‐effects or antibody‐mediated resistance occurred. Conclusion:: This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Codrin Lungu MD,</name><affiliations><json:string>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>Barbara I. Karp MD,</name><affiliations><json:string>Combined Neuroscience IRB, National Institutes of Health, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>Katharine Alter MD,</name><affiliations><json:string>Physical Disabilities Section, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>Regina Zolbrod,</name><affiliations><json:string>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>Mark Hallett MD</name><affiliations><json:string>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>botulinum</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>focal hand dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>safety</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>efficacy</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Background:: Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more. Methods:: Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using t tests and Pearson correlations. Results:: Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side‐effects, but benefit magnitude predicted longer compliance. No serious side‐effects or antibody‐mediated resistance occurred. Conclusion:: This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.956</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1111</abstractCharCount><pdfWordCount>27035</pdfWordCount><pdfCharCount>175924</pdfCharCount><pdfPageCount>43</pdfPageCount><abstractWordCount>163</abstractWordCount></qualityIndicators><title>Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title><genre><json:string>Serial article</json:string></genre><host><volume>26</volume><pages><total>4</total><last>753</last><first>750</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23504</json:string></doi><id>B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2011</date></publicationStmt><notesStmt><note>Author Roles and Disclosures</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report Full financial disclosures and author roles can be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title><author><persName><forename type="first">Codrin</forename><surname>Lungu</surname><roleName type="degree">MD,</roleName></persName><affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</affiliation></author><author><persName><forename type="first">Barbara I.</forename><surname>Karp</surname><roleName type="degree">MD,</roleName></persName><affiliation>Combined Neuroscience IRB, National Institutes of Health, Bethesda, Maryland, USA</affiliation></author><author><persName><forename type="first">Katharine</forename><surname>Alter</surname><roleName type="degree">MD,</roleName></persName><affiliation>Physical Disabilities Section, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA</affiliation></author><author><persName><forename type="first">Regina</forename><surname>Zolbrod,</surname></persName><affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</affiliation></author><author><persName><forename type="first">Mark</forename><surname>Hallett</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: NIH Medical Neurology, Bldg 10, Rm 7D37, MSC 1428, 10 Center Dr, Bethesda, MD 20892, USA</p></note><affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-03"></date><biblScope unit="vol">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="750">750</biblScope><biblScope unit="page" to="753">753</biblScope></imprint></monogr><idno type="istex">B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D</idno><idno type="DOI">10.1002/mds.23504</idno><idno type="ArticleID">MDS23504</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background:: Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more. Methods:: Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using t tests and Pearson correlations. Results:: Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side‐effects, but benefit magnitude predicted longer compliance. No serious side‐effects or antibody‐mediated resistance occurred. Conclusion:: This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>botulinum</term></item><item><term>dystonia</term></item><item><term>focal hand dystonia</term></item><item><term>safety</term></item><item><term>efficacy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-04-29">Received</change><change when="2010-10-03">Registration</change><change when="2011-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v26.4</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2011-03">March 2011</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="330" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23504</doi><idGroup><id type="unit" value="MDS23504"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-04-29"></event><event type="manuscriptRevised" date="2010-07-23"></event><event type="manuscriptAccepted" date="2010-10-03"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-02-01"></event><event type="publishedOnlineFinalForm" date="2011-04-19"></event><event type="firstOnline" date="2011-02-01"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">750</numbering><numbering type="pageLast">753</numbering></numberingGroup><correspondenceTo>NIH Medical Neurology, Bldg 10, Rm 7D37, MSC 1428, 10 Center Dr, Bethesda, MD 20892, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23504.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="2672"></count></countGroup><titleGroup><title type="main" xml:lang="en">Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more<link href="#fn1"></link></title><title type="short" xml:lang="en">Long‐Term Botulinum in Focal Hand Dystonia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Codrin</givenNames><familyName>Lungu</familyName><degrees>MD,</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Barbara I.</givenNames><familyName>Karp</familyName><degrees>MD,</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Katharine</givenNames><familyName>Alter</familyName><degrees>MD,</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Regina</givenNames><familyName>Zolbrod,</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Mark</givenNames><familyName>Hallett</familyName><degrees>MD</degrees></personName><contactDetails><email>hallettm@ninds.nih.gov</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Combined Neuroscience IRB, National Institutes of Health, Bethesda, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Physical Disabilities Section, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">botulinum</keyword><keyword xml:id="kwd2">dystonia</keyword><keyword xml:id="kwd3">focal hand dystonia</keyword><keyword xml:id="kwd4">safety</keyword><keyword xml:id="kwd5">efficacy</keyword></keywordGroup><supportingInformation><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23504:MDS_23504_sm_authorroles"></mediaResource><caption>Author Roles and Disclosures</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using <i>t</i> tests and Pearson correlations.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side‐effects, but benefit magnitude predicted longer compliance. No serious side‐effects or antibody‐mediated resistance occurred.</p></section><section xml:id="abs1-4"><title type="main">Conclusion:</title><p>This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Relevant conflicts of interest/financial disclosures: Nothing to report Full financial disclosures and author roles can be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Long‐Term Botulinum in Focal Hand Dystonia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more</title></titleInfo><name type="personal"><namePart type="given">Codrin</namePart><namePart type="family">Lungu</namePart><namePart type="termsOfAddress">MD,</namePart><affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Barbara I.</namePart><namePart type="family">Karp</namePart><namePart type="termsOfAddress">MD,</namePart><affiliation>Combined Neuroscience IRB, National Institutes of Health, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Katharine</namePart><namePart type="family">Alter</namePart><namePart type="termsOfAddress">MD,</namePart><affiliation>Physical Disabilities Section, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Regina</namePart><namePart type="family">Zolbrod,</namePart><affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark</namePart><namePart type="family">Hallett</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA</affiliation><description>Correspondence: NIH Medical Neurology, Bldg 10, Rm 7D37, MSC 1428, 10 Center Dr, Bethesda, MD 20892, USA</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-03</dateIssued><dateCaptured encoding="w3cdtf">2010-04-29</dateCaptured><dateValid encoding="w3cdtf">2010-10-03</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">24</extent><extent unit="words">2672</extent></physicalDescription><abstract lang="en">Background:: Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more. Methods:: Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using t tests and Pearson correlations. Results:: Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side‐effects, but benefit magnitude predicted longer compliance. No serious side‐effects or antibody‐mediated resistance occurred. Conclusion:: This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society</abstract><note type="additional physical form">Author Roles and Disclosures</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report Full financial disclosures and author roles can be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>botulinum</topic><topic>dystonia</topic><topic>focal hand dystonia</topic><topic>safety</topic><topic>efficacy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>750</start><end>753</end><total>4</total></extent></part></relatedItem><identifier type="istex">B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D</identifier><identifier type="DOI">10.1002/mds.23504</identifier><identifier type="ArticleID">MDS23504</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000B35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B8AD6CE12A929C49F3849F0B1ADB9F4A2218E81D
|texte= Long‐term follow‐up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more
}}
| This area was generated with Dilib version V0.6.23. |  |